Thermo Fisher Posts Strong Q4 Earnings Boosting Stock

By Patricia Miller

Jan 31, 2025

2 min read

Thermo Fisher Scientific's Q4 results show increased earnings and revenue, with strong product launches and a positive outlook for future growth.

Scientist in Protective Gear Operating Advanced Laboratory Equipment in Sterile Environment

What You Need To Know

Thermo Fisher Scientific (NYSE: TMO) recently announced its fourth-quarter adjusted earnings, reporting $6.10 per diluted share, a notable increase from $5.67 in the previous year and surpassing analyst expectations of $5.94. The company also achieved a quarterly revenue of $11.40 billion, up from $10.89 billion year-over-year, which exceeded the anticipated $11.28 billion by analysts. Following this strong performance, Thermo Fisher's stock ascended by 6.6%.

Key growth was driven by the analytical instruments division with the introduction of new products, including the iCAP MX Series ICP-MS and Gibco CTS Detachable Dynabeads. The company maintained consistent full-year revenue of $42.88 billion. Additionally, Thermo Fisher completed the acquisition of Olink and returned $4.6 billion to shareholders.

Looking ahead, the company projects 2025 adjusted earnings per share between $23.10 and $23.50, which is above market forecasts. Thermo Fisher's CEO, Marc Casper, expects future growth to be fueled by market share expansion and strategic partnerships, although the company currently holds $29.06 billion in long-term obligations.

Sign up for Investing Intel Newsletter

Get the latest news and updates from our team.

I agree to the privacy policy.

Why This Is Important for Retail Investors

  1. Earnings Growth: Thermo Fisher's increase in adjusted earnings per share demonstrates strong financial performance, signaling potential stability and profitability for investors.

  2. Revenue Exceeding Expectations: The company’s ability to surpass revenue forecasts indicates robust demand for its products, which may lead to future growth opportunities.

  3. Strategic Acquisitions: The acquisition of Olink reflects Thermo Fisher’s commitment to enhancing its market position, offering investors a sign of expanding business operations.

  4. Shareholder Returns: The significant return of $4.6 billion to shareholders highlights the company’s dedication to enhancing shareholder value, which can attract income-focused investors.

  5. Positive Market Outlook: Projections for future earnings growth, along with anticipated market share gains, suggest a favorable long-term investment prospect for retail investors.

Relevant ETFs

Some investors prefer to invest in stocks via an exchange-traded fund for ease and reduced risk. Some relevant ETFs include the following:

  • SPDR S&P Biotech ETF

  • iShares Nasdaq Biotechnology ETF

  • Invesco S&P 500 Equal Weight Health Care ETF

  • Vanguard Health Care ETF

  • iShares U.S. Medical Devices ETF

  • ARK Genomic Revolution ETF

S&P 500: Winners & Losers 2024

Related Articles:

Explore more on these topics:

Pharmaceuticals Biotechnology Growth Investing Quarterly Earnings Annual Earnings Healthcare Industrials Information Technology

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.